Italy Glioma Diagnosis Treatment Market

ID: MRFR/HC/52771-HCR
200 Pages
Vikita Thakur
Last Updated: February 06, 2026
Italy Glioma Diagnosis and Treatment Market Research Report By Type (Primary Tumors, Secondary Tumors), By Diagnosis (Neurological Exam, CT Scan, MRI, PET Scan, Biopsy, Molecular Testing, EEG, Others), By Treatment (Surgery, Chemotherapy, Radiation Therapy, Immunotherapy, Targeted Therapy), By Grade (Low Grade Glioma, High Grade Glioma, Recurrent High Grade Glioma), By Location (Supratentorial, Infratentorial) and By End User (Hospitals & Clinics, Diagnostic Centers, Medical Research Centers, Others) - Growth & Industry Forecast 2025 To 2035
Italy Glioma Diagnosis Treatment Market
Market Size
Forecast Period2025 - 2035
CAGR (2025 - 2035)5.31%
2024 Market Size$ 89.42 Million
2025 Market Size$ 94.17 Million
2035 Market Size$ 158 Million
Key Players
Roche
Novartis
Merck
Bristol-Myers Squibb
Eli Lilly
Amgen
Trends
  • Advancements in Diagnostic Technologies
  • Personalized Treatment Approaches
  • Collaborative Research Initiatives
Opportunities
  • Rising Incidence of Glioma Cases
  • Growing Demand for Targeted Therapies
  • Government Funding for Cancer Research
Summary Table of Contents Segmentation Download PDF
  1. 1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
    1. 1.1 EXECUTIVE SUMMARY
      1. 1.1.1 Market Overview
      2. 1.1.2 Key Findings
      3. 1.1.3 Market Segmentation
      4. 1.1.4 Competitive Landscape
      5. 1.1.5 Challenges and Opportunities
      6. 1.1.6 Future Outlook
  2. 2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
    1. 2.1 MARKET INTRODUCTION
      1. 2.1.1 Definition
      2. 2.1.2 Scope of the study
        1. 2.1.2.1 Research Objective
        2. 2.1.2.2 Assumption
        3. 2.1.2.3 Limitations
    2. 2.2 RESEARCH METHODOLOGY
      1. 2.2.1 Overview
      2. 2.2.2 Data Mining
      3. 2.2.3 Secondary Research
      4. 2.2.4 Primary Research
        1. 2.2.4.1 Primary Interviews and Information Gathering Process
        2. 2.2.4.2 Breakdown of Primary Respondents
      5. 2.2.5 Forecasting Model
      6. 2.2.6 Market Size Estimation
        1. 2.2.6.1 Bottom-Up Approach
        2. 2.2.6.2 Top-Down Approach
      7. 2.2.7 Data Triangulation
      8. 2.2.8 Validation
  3. 3 SECTION III: QUALITATIVE ANALYSIS
    1. 3.1 MARKET DYNAMICS
      1. 3.1.1 Overview
      2. 3.1.2 Drivers
      3. 3.1.3 Restraints
      4. 3.1.4 Opportunities
    2. 3.2 MARKET FACTOR ANALYSIS
      1. 3.2.1 Value chain Analysis
      2. 3.2.2 Porter's Five Forces Analysis
        1. 3.2.2.1 Bargaining Power of Suppliers
        2. 3.2.2.2 Bargaining Power of Buyers
        3. 3.2.2.3 Threat of New Entrants
        4. 3.2.2.4 Threat of Substitutes
        5. 3.2.2.5 Intensity of Rivalry
      3. 3.2.3 COVID-19 Impact Analysis
        1. 3.2.3.1 Market Impact Analysis
        2. 3.2.3.2 Regional Impact
        3. 3.2.3.3 Opportunity and Threat Analysis
  4. 4 SECTION IV: QUANTITATIVE ANALYSIS
    1. 4.1 Chemicals and Materials, BY Type (USD Million)
      1. 4.1.1 Primary Tumors
      2. 4.1.2 Secondary Tumors
    2. 4.2 Chemicals and Materials, BY Diagnosis (USD Million)
      1. 4.2.1 Neurological Exam
      2. 4.2.2 CT Scan
      3. 4.2.3 MRI
      4. 4.2.4 PET Scan
      5. 4.2.5 Biopsy
      6. 4.2.6 Molecular Testing
      7. 4.2.7 EEG
      8. 4.2.8 Others
    3. 4.3 Chemicals and Materials, BY Treatment (USD Million)
      1. 4.3.1 Surgery
      2. 4.3.2 Chemotherapy
      3. 4.3.3 Radiation Therapy
      4. 4.3.4 Immunotherapy
      5. 4.3.5 Targeted Therapy
    4. 4.4 Chemicals and Materials, BY Grade (USD Million)
      1. 4.4.1 Low Grade Glioma
      2. 4.4.2 High Grade Glioma
      3. 4.4.3 Recurrent High Grade Glioma
    5. 4.5 Chemicals and Materials, BY Location (USD Million)
      1. 4.5.1 Supratentorial
      2. 4.5.2 Infratentorial
    6. 4.6 Chemicals and Materials, BY End User (USD Million)
      1. 4.6.1 Hospitals & Clinics
      2. 4.6.2 Diagnostic Centers
      3. 4.6.3 Medical Research Centers
      4. 4.6.4 Others
  5. 5 SECTION V: COMPETITIVE ANALYSIS
    1. 5.1 Competitive Landscape
      1. 5.1.1 Overview
      2. 5.1.2 Competitive Analysis
      3. 5.1.3 Market share Analysis
      4. 5.1.4 Major Growth Strategy in the Chemicals and Materials
      5. 5.1.5 Competitive Benchmarking
      6. 5.1.6 Leading Players in Terms of Number of Developments in the Chemicals and Materials
      7. 5.1.7 Key developments and growth strategies
        1. 5.1.7.1 New Product Launch/Service Deployment
        2. 5.1.7.2 Merger & Acquisitions
        3. 5.1.7.3 Joint Ventures
      8. 5.1.8 Major Players Financial Matrix
        1. 5.1.8.1 Sales and Operating Income
        2. 5.1.8.2 Major Players R&D Expenditure. 2023
    2. 5.2 Company Profiles
      1. 5.2.1 Roche (CH)
        1. 5.2.1.1 Financial Overview
        2. 5.2.1.2 Products Offered
        3. 5.2.1.3 Key Developments
        4. 5.2.1.4 SWOT Analysis
        5. 5.2.1.5 Key Strategies
      2. 5.2.2 Novartis (CH)
        1. 5.2.2.1 Financial Overview
        2. 5.2.2.2 Products Offered
        3. 5.2.2.3 Key Developments
        4. 5.2.2.4 SWOT Analysis
        5. 5.2.2.5 Key Strategies
      3. 5.2.3 Merck (DE)
        1. 5.2.3.1 Financial Overview
        2. 5.2.3.2 Products Offered
        3. 5.2.3.3 Key Developments
        4. 5.2.3.4 SWOT Analysis
        5. 5.2.3.5 Key Strategies
      4. 5.2.4 Bristol-Myers Squibb (US)
        1. 5.2.4.1 Financial Overview
        2. 5.2.4.2 Products Offered
        3. 5.2.4.3 Key Developments
        4. 5.2.4.4 SWOT Analysis
        5. 5.2.4.5 Key Strategies
      5. 5.2.5 Eli Lilly (US)
        1. 5.2.5.1 Financial Overview
        2. 5.2.5.2 Products Offered
        3. 5.2.5.3 Key Developments
        4. 5.2.5.4 SWOT Analysis
        5. 5.2.5.5 Key Strategies
      6. 5.2.6 Amgen (US)
        1. 5.2.6.1 Financial Overview
        2. 5.2.6.2 Products Offered
        3. 5.2.6.3 Key Developments
        4. 5.2.6.4 SWOT Analysis
        5. 5.2.6.5 Key Strategies
      7. 5.2.7 AstraZeneca (GB)
        1. 5.2.7.1 Financial Overview
        2. 5.2.7.2 Products Offered
        3. 5.2.7.3 Key Developments
        4. 5.2.7.4 SWOT Analysis
        5. 5.2.7.5 Key Strategies
      8. 5.2.8 Pfizer (US)
        1. 5.2.8.1 Financial Overview
        2. 5.2.8.2 Products Offered
        3. 5.2.8.3 Key Developments
        4. 5.2.8.4 SWOT Analysis
        5. 5.2.8.5 Key Strategies
      9. 5.2.9 Bayer (DE)
        1. 5.2.9.1 Financial Overview
        2. 5.2.9.2 Products Offered
        3. 5.2.9.3 Key Developments
        4. 5.2.9.4 SWOT Analysis
        5. 5.2.9.5 Key Strategies
    3. 5.3 Appendix
      1. 5.3.1 References
      2. 5.3.2 Related Reports
  6. 6 LIST OF FIGURES
    1. 6.1 MARKET SYNOPSIS
    2. 6.2 ITALY MARKET ANALYSIS BY TYPE
    3. 6.3 ITALY MARKET ANALYSIS BY DIAGNOSIS
    4. 6.4 ITALY MARKET ANALYSIS BY TREATMENT
    5. 6.5 ITALY MARKET ANALYSIS BY GRADE
    6. 6.6 ITALY MARKET ANALYSIS BY LOCATION
    7. 6.7 ITALY MARKET ANALYSIS BY END USER
    8. 6.8 KEY BUYING CRITERIA OF CHEMICALS AND MATERIALS
    9. 6.9 RESEARCH PROCESS OF MRFR
    10. 6.10 DRO ANALYSIS OF CHEMICALS AND MATERIALS
    11. 6.11 DRIVERS IMPACT ANALYSIS: CHEMICALS AND MATERIALS
    12. 6.12 RESTRAINTS IMPACT ANALYSIS: CHEMICALS AND MATERIALS
    13. 6.13 SUPPLY / VALUE CHAIN: CHEMICALS AND MATERIALS
    14. 6.14 CHEMICALS AND MATERIALS, BY TYPE, 2024 (% SHARE)
    15. 6.15 CHEMICALS AND MATERIALS, BY TYPE, 2024 TO 2035 (USD Million)
    16. 6.16 CHEMICALS AND MATERIALS, BY DIAGNOSIS, 2024 (% SHARE)
    17. 6.17 CHEMICALS AND MATERIALS, BY DIAGNOSIS, 2024 TO 2035 (USD Million)
    18. 6.18 CHEMICALS AND MATERIALS, BY TREATMENT, 2024 (% SHARE)
    19. 6.19 CHEMICALS AND MATERIALS, BY TREATMENT, 2024 TO 2035 (USD Million)
    20. 6.20 CHEMICALS AND MATERIALS, BY GRADE, 2024 (% SHARE)
    21. 6.21 CHEMICALS AND MATERIALS, BY GRADE, 2024 TO 2035 (USD Million)
    22. 6.22 CHEMICALS AND MATERIALS, BY LOCATION, 2024 (% SHARE)
    23. 6.23 CHEMICALS AND MATERIALS, BY LOCATION, 2024 TO 2035 (USD Million)
    24. 6.24 CHEMICALS AND MATERIALS, BY END USER, 2024 (% SHARE)
    25. 6.25 CHEMICALS AND MATERIALS, BY END USER, 2024 TO 2035 (USD Million)
    26. 6.26 BENCHMARKING OF MAJOR COMPETITORS
  7. 7 LIST OF TABLES
    1. 7.1 LIST OF ASSUMPTIONS
  8. 7.1.1
    1. 7.2 Italy MARKET SIZE ESTIMATES; FORECAST
      1. 7.2.1 BY TYPE, 2025-2035 (USD Million)
      2. 7.2.2 BY DIAGNOSIS, 2025-2035 (USD Million)
      3. 7.2.3 BY TREATMENT, 2025-2035 (USD Million)
      4. 7.2.4 BY GRADE, 2025-2035 (USD Million)
      5. 7.2.5 BY LOCATION, 2025-2035 (USD Million)
      6. 7.2.6 BY END USER, 2025-2035 (USD Million)
    2. 7.3 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
  9. 7.3.1
    1. 7.4 ACQUISITION/PARTNERSHIP
  10. 7.4.1

Italy Glioma Diagnosis Treatment Market Segmentation

Italy Glioma Diagnosis Treatment Market By Type (USD Million, 2025-2035)

  • Primary Tumors
  • Secondary Tumors

Italy Glioma Diagnosis Treatment Market By Diagnosis (USD Million, 2025-2035)

  • Neurological Exam
  • CT Scan
  • MRI
  • PET Scan
  • Biopsy
  • Molecular Testing
  • EEG
  • Others

Italy Glioma Diagnosis Treatment Market By Treatment (USD Million, 2025-2035)

  • Surgery
  • Chemotherapy
  • Radiation Therapy
  • Immunotherapy
  • Targeted Therapy

Italy Glioma Diagnosis Treatment Market By Grade (USD Million, 2025-2035)

  • Low Grade Glioma
  • High Grade Glioma
  • Recurrent High Grade Glioma

Italy Glioma Diagnosis Treatment Market By Location (USD Million, 2025-2035)

  • Supratentorial
  • Infratentorial

Italy Glioma Diagnosis Treatment Market By End User (USD Million, 2025-2035)

  • Hospitals & Clinics
  • Diagnostic Centers
  • Medical Research Centers
  • Others

Related Reports

No regional reports available for this market.

No country-specific reports available for this market.

Customer Stories

Case Study Cover Image
Case Study

Aerospace & Defense

Future of Dismounted Soldier Systems Market Trends & Adoption Roadmap 2019–2035
Download PDF ×

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.